guiding you onto the right path

Latest Jobs

Purpose: Acting as the key interface with clients over projects, manages the timely delivery of project outputs in line with client expectations. Dev...
Purpose: Manages the delivery of client project(s), ensuring delivery of the project in line with client objectives and expectations as well as proje...

HEOR Analyst

Overview of the role

Analyst is the normal entry level for those who have just completed a Masters degree in Health Economics or (less frequently) a similar Masters course. Analysts have an important role within the HEOR practice and are expected to develop their skills and knowledge by taking on a wide range of tasks whilst maximising opportunities to learn from colleagues. All Analysts have a mentor at Senior Consultant level or above, who is responsible for supporting their professional development and ensuring that they receive the expected range of experience and formal training. Analysts also have the opportunity to contribute to business development, mainly by drafting proposals in response to RFPs.

 

REQUIRED KNOWLEDGE

A good knowledge of HEOR methods and approaches and a understanding of the health care sector and the pharmaceutical market, gained through study and (ideally) internships or previous healthcare experience.

RESPONSIBILITIES

General

  • Carry out work relating to the HEOR business areas (health economic modelling, HTA submissions, value communication, market access strategy and outcomes research) to a high standard which meets or exceeds client expectations.
  • Work with supervision independently and/or as part of a project team on defined tasks.
  • Produce draft reports relating to ad-hoc HEOR projects if required.

 

Business development / internal initiatives

  • Produce partial initial drafts of proposals based on client RFPs and supporting information.
  • Participate in internal initiatives eg internal disseminations and make oral presentations to colleagues if required, supported by more senior colleagues.

 

Project management / Client liaison

  • Assist on specific project or client management tasks under the supervision of a more senior colleague
  • Attend client and other external meetings in the home base country and elsewhere in Europe and the US, accompanied by a more senior colleague
  • Make oral presentations of own research / analysis to clients

 

 

Product-specific

Health economic modelling

  • Produce draft analysis plans for simple health economic models and provide input to their further development.
  • Input to the development of complex health economic models.
  • Review literature to source the required inputs (costs and clinical) to health economics models and analyses. Input this data to models if necessary.
  • Produce support materials for completed economic models, e.g. reports and training programmes.

 

HTA submissions

  • Write chapters of submission documents for national and international HTA, market access and reimbursement organisations (NICE, SMC, PBAC etc).

 

Literature and data review

  • With support, develop search strategies for structured and systematic literature reviews.
  • Carry out abstract review, paper selection and data extraction.
  • Write literature review reports.
  • Carry out grey literature reviews
  • Assist specialists within the HEOR team in conducting meta analyses and indirect comparisons.

 

Medical writing for value communication

  • Write clinical and economic chapters for product value dossiers and value communications support material for clients, including the development of value messages.
  • Draft abstracts, posters and manuscripts for publication based on economic models, literature reviews, meta-analyses and other HEOR work. Assist in the submission process.

 

Retrospective data analysis

  • Extract data from databases for outcomes research projects and support materials e.g. protocols.
  • Draft sections of reports for clients, eg methodology.

 

Market access strategy

  • Carry out research and draft reports for projects delivering strategic advice to clients on pricing, reimbursement and market access.

 

 

QUALIFICATIONS, EXPERIENCE, TECHNICAL AND PERSONAL SKILLLS

 

Essential qualifications

  • MSc in science, economics or a related discipline
  • Postgraduate qualification in health economics, health services research or a relevant related area.

 

Essential personal skills and behaviours

  • Fluency in English (spoken and written); strong business/scientific written English
  • Strong written and verbal communication skills
  • A commitment to working collaboratively and effectively with others in and across the team to accomplish goals
  • A commitment to timely internal and client communication; with clients, project managers and team members,  colleagues and others
  • Good team-based interpersonal skills but also an ability to work independently
  • A pragmatic and logical problem solving approach to projects
  • Strong attention to detail on all project deliverables even under time pressure.
  • Good time management and personal organisational skills
  • An enthusiastic and flexible approach to work within the HEOR business area and willingness to contribute to all types of project undertaken by the team.

 

Essential general technical skills and knowledge

  • Numerate and good quantitative skills - able to work in Excel to at least Intermediate level and able to provide evidence of this applied in A work or academic setting
  • Competency in using Word and PowerPoint and an interest in learning relevant decision-support and statistical packages
  • High level of literacy – able to appraise evidence critically and write reports and manuscripts in clear, concise language as required by the type of work.
  • Ability to quality check own work so that drafts are delivered with only minimal minor typographical errors
  • Good understanding of outcomes research and/or economic theory and the ability to apply this in practice

 

 

Desirable general technical skills and knowledge

  • Good understanding of and interest in the international health care environment
  • Commercial awareness and good understanding of the health technology and pharmaceutical industry

 

Desirable experience

  • Post graduate work experience in a related area such as economics, health economics, statistics, psychology or science

 

  • Experience of working in health economics/outcomes research/health services research.

 

  • Experience in undertaking economic analysis in one of the following environments:
  • Pharmaceutical or other Healthcare Industry
  • Academic Organisation   
  • Health Technology Assessment Group
  • Health Services Research
Job Type:
Permanent
Experience:
Bachelors Degree
Location:
London
Sector:
Health Economics & Outcomes Research
Salary:
£Negotiable
Ref:
103

How to apply

Apply Now

Latest News

Fri, 27 Jun 2025 10:00:00 +0200
Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.
Thu, 26 Jun 2025 10:00:00 +0200
Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.
Wed, 25 Jun 2025 10:00:00 +0200
An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.
Tue, 24 Jun 2025 10:00:00 +0200
A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Mon, 23 Jun 2025 10:00:00 +0200
Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.
Fri, 20 Jun 2025 10:00:00 +0200
In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the potential to be more accurate at inverse protein folding than existing state-of-the-art methods.
Thu, 19 Jun 2025 10:00:00 +0200
AstraZenecaAstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
Wed, 18 Jun 2025 10:00:00 +0200
Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as the body ages, the activity of brown adipose tissue decreases. This inactivation of brown adipose tissue - also typical of obese people - remains poorly studied in the scientific literature.
Tue, 17 Jun 2025 10:00:00 +0200
Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted cancer cells in mice into healthy nerve cells. The study is published in the journal Proceedings of the National Academy of Sciences (PNAS).
Mon, 16 Jun 2025 10:00:00 +0200
Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines. As recently published in Nature Communications, Jinze Liu, Ph.D., and Kevin Byrd, D.D.S., Ph.D., created Threshold-based Assignment of Cell Types from Multiplexed Imaging Data (TACIT), which assigns cell identities based on cell-marker expression profiles.
Fri, 13 Jun 2025 10:00:00 +0200
A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) and Roche.

The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patients.

Thu, 12 Jun 2025 10:00:00 +0200
BayerVividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020.
Wed, 11 Jun 2025 10:00:00 +0200
We have all heard of antibodies - proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system. But not all of us are familiar with aptamers: short segments of DNA or RNA that are designed to bind, like antibodies, to specific targets. Synthetic and inexpensive to produce, aptamers are attractive alternatives to antibodies for biomedical diagnostics and therapeutics.
Tue, 10 Jun 2025 10:00:00 +0200
Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses - the dried edible seeds of legumes - that increased their antioxidant and antidiabetic properties and their soluble protein content.

Using the bacteria Lactiplantibacillus plantarum 299v as the microorganism, the team fermented pulses obtained from varying concentrations of black bean, black-eyed pea, green split pea, red lentil and pinto bean flours.

Mon, 09 Jun 2025 10:00:00 +0200
In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population.
Fri, 06 Jun 2025 10:00:00 +0200
SanofiNew data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.
Thu, 05 Jun 2025 10:00:00 +0200
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.
Wed, 04 Jun 2025 10:00:00 +0200
University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis.

Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.

Tue, 03 Jun 2025 10:00:00 +0200
New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live longer.

The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.

Mon, 02 Jun 2025 10:00:00 +0200
Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not only expensive but also time-consuming, rendering comprehensive testing a challenging task.

Upload Your CV

Need help finding that new job? Leave your details with us and request a call back from one of our consultants.

Submit A Vacancy

Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you